Godavari Biorefineries secured a patent by the China National Intellectual Property Administration (CNIPA) for its novel anti-cancer molecule, the company announced on Tuesday.
The company, through its clinical-stage biotech division Sathgen Therapeutics, has been granted this patent by China’s patent and trademark office for the anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE.
This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer.
“This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide," said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Ltd.
The company, through its clinical-stage biotech division Sathgen Therapeutics, has been granted this patent by China’s patent and trademark office for the anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE.
This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer.
“This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide," said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Ltd.
